NeoGraph Analytics
Medical DevicesGlobal2026 – 2032

Hearing Aids Market Size, Share & Forecast 2026-2032

Hearing aids market at $9.37B in 2026, reaching $13.67B by 2032 at 6.5% — and why 23.16 million units at retail prices means consumers spend about $31B.

Revenue, 2026

$9.4B

Forecast, 2032

$13.7B

CAGR, 2026-2032

6.5%

Report Coverage

Global

Code: hearing-aids-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

Hearing aids is the best-instrumented market in this batch, and that is what makes its central defect provable rather than arguable. An industry trade body publishes unit shipments, four of the five major manufacturers publish revenue, one of them publishes wholesale and retail separately in the same statement, and a large buyer survey publishes measured transaction prices. Put them together and the published market sizes are revealed as a single unstated scope decision. EHIMA's members sold 23.16 million hearing aids globally in 2025; divide the published totals by that count and you get $380 to $652 per aid, which is a factory-gate price. HearingTracker's survey of more than 1,100 buyers puts the measured average at $2,694 per pair, or $1,347 per aid, so consumer spend on those same units is roughly $31.2 billion — about 3.5 times the $8.8 billion headline. Demant proves the two tiers from inside one company: 2025 retail clinic revenue of DKK 10,724 million, up 8%, against external wholesale hearing-aid revenue of DKK 9,841 million, down 2%. Four manufacturers' disclosed revenue totals about $11,769 million, exceeding three of the five published figures, with Starkey absent and Amplifon outside every definition — and the excess reconciles exactly once retail is stripped out, landing the manufacturer tier back at roughly $8 to $9 billion. We publish that tier: $9.37 billion in 2026 to $13.67 billion by 2032 at 6.5%. The warning attached is that unit growth has fallen from 7.7% to 2.1% in two years, measured consumer prices are down 42% since 2018 following the FDA's October 2022 over-the-counter rule, and the manufacturers' own 2025 growth was 2 to 3%.

02

Key Highlights

1

Headline

$9.37 billion in 2026 to $13.67 billion in 2032 at 6.5%, interpolated from Global Market Insights' own published 2025 base and rate — the manufacturer tier

2

EHIMA members sold 23.16 million hearing aids globally in 2025, so the published totals work out at $380 to $652 per aid: a factory-gate price, not a retail one

3

At HearingTracker's measured $1,347 per aid, consumer spend on those 23.16 million units is roughly $31.2 billion — about 3.5x the published figure

4

Demant's 2025 retail revenue (DKK 10,724 million, +8%) exceeded its own external wholesale hearing-aid revenue (DKK 9,841 million, -2%), proving the two tiers from inside one company

5

Four manufacturers disclose about $11,769 million between them — 1.34x Global Market Insights' $8.8 billion — with Starkey absent and Amplifon outside every published definition

6

The excess reconciles: stripping retail out lands the manufacturer tier back at roughly $8 to $9 billion, which is the published figure almost exactly

7

Unit growth has decelerated from 7.7% (2023) to 4.0% (2024) to 2.1% (2025), against published CAGRs of 5.6% to 11.7%

8

Measured consumer prices per pair fell 42% between 2018 and 2026, following the FDA over-the-counter rule effective 17 October 2022; OTC pairs transact at $502 against $3,432 prescription private pay

03

Market Overview

Market Context

Hearing aids are sold twice, and the research industry sizes only the first sale. A manufacturer makes a device and sells it at a factory-gate price of a few hundred dollars; a dispenser fits it, tunes it, follows the patient up and charges a bundled price several times higher. The published market figures measure the first transaction. They are approximately right for it — our reconciliation of disclosed manufacturer revenue lands within a few hundred million dollars of Global Market Insights' $8.8 billion for 2025 — and they are roughly 3.5 times too small for the thing most readers assume a market size means. The proof is available because this industry publishes unusually well. EHIMA gives units: 23.16 million in 2025. HearingTracker's buyer survey gives measured prices: $2,694 per pair. And Demant, uniquely, reports both tiers in one statement and shows retail revenue exceeding wholesale revenue inside the same company. The structural consequence is that the four groups with manufacturing businesses are all buying their way down the chain — Demant grew retail revenue 8% in a year when its wholesale fell 2%, and Sonova has renamed its two businesses Wholesale and Retail — while a pure retailer like Amplifon operates entirely outside every published definition of the market. Underneath all of it sits the number that frames the opportunity and the failure together: 23.16 million units sold a year against the 1.5 billion people WHO counts with some degree of hearing loss.

This is the best-instrumented market in this batch and the one where a single unstated scope decision does the most damage. EHIMA's member companies sold 23.16 million hearing aids globally in 2025. Divide the published market sizes by that count and you get $380 to $652 per hearing aid — a factory-gate price. HearingTracker's survey of more than 1,100 buyers puts the measured average transaction at $2,694 a pair, or $1,347 an aid, so consumer spend on those 23.16 million units is roughly $31 billion, about 3.5 times the published figure. Demant proves the two-tier structure from inside one company: its retail revenue of DKK 10,724 million in 2025 exceeded its wholesale hearing-aid revenue of DKK 9,841 million. Four manufacturers' disclosed revenue totals about $11,769 million, which is 1.34x the published market — and the excess reconciles exactly once retail is stripped out, landing back on the manufacturer tier. We publish that tier, Global Market Insights' September 2025 series: $9.37 billion in 2026 to $13.67 billion by 2032 at 6.5%. The caution is that unit growth has decelerated to 2.1%, measured consumer prices are down 42% since 2018, and the manufacturers' own 2025 growth was roughly 2 to 3%.

Market Stage

Mature

Adoption Level

23.16 million units a year against 1.5 billion people with some hearing loss

Key Trends

Unit growth is decelerating sharply: EHIMA members sold 21.81 million aids in 2023 (+7.7%), 22.69 million in 2024 (+4.0%) and 23.16 million in 2025 (+2.1%)Measured consumer prices have collapsed: HearingTracker's buyer survey puts the average at $2,694 a pair against $4,672 in 2018, a 42% fall, with over-the-counter pairs transacting at $502 against $3,432 for prescription private-payThe FDA's over-the-counter rule is the mechanism: published 17 August 2022 and effective 17 October 2022, it created an OTC category for adults with perceived mild-to-moderate loss and repealed the prior conditions for sale, with legacy devices required to comply by 14 April 2023Retail is where the money now is, and the manufacturers know it: Demant's Hearing Care clinic revenue rose 8% to DKK 10,724 million in 2025 while its external wholesale hearing-aid revenue fell 2% to DKK 9,841 millionManufacturer growth is near zero at the top of the industry: WS Audiology posted 0% organic growth in FY2024/25 on reduced United States benefit coverage, Demant's wholesale fell 2%, and GN's Hearing division grew 5% organic after 10% and 13% in the two prior yearsPortfolio reshaping is under way: Sonova is divesting Consumer Hearing, now reported as discontinued operations, and renamed its Hearing Instruments business Wholesale and its Audiological Care business Retail with the FY2025/26 results
04

Market Forecast & Data

Market Growth Forecast
2026-2032 · CAGR 6.5%

Base Year (2026)

$9.4B

Forecast (2032)

$13.7B

CAGR (2026-2032)

6.5%

Market size by year, 2026-2032, in USD Billion.
YearMarket size ($ Billion)
2026Base year$9.37B
2027$9.98B
2028$10.63B
2029$11.32B
2030$12.06B
2031$12.84B
2032$13.67B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. Modelled at a constant 6.5% CAGR from Global Market Insights' published 2025 base; manufacturer tier. How these figures are produced.
Forecast Analysis

Our 6.5% is Global Market Insights' own rate on its own base, and the series reproduces that rate exactly. Whether 6.5% is defensible for the manufacturer tier is the harder question, and the evidence says it sits at the optimistic end of what the disclosed record supports. Three independent series all point lower. EHIMA's unit shipments decelerated from 7.7% growth in 2023 to 4.0% in 2024 to 2.1% in 2025. HearingTracker's measured consumer price per pair fell 42% between 2018 and 2026, with over-the-counter devices transacting at $502 against $3,432 for a prescription private-pay pair — the direct consequence of the FDA rule effective 17 October 2022. And the manufacturers themselves grew roughly 2 to 3% in 2025: Demant's external wholesale revenue down 2%, WS Audiology 0% organic on reduced United States benefit coverage, GN 5% organic after 10% and 13% in the two prior years. Sonova is the exception, with Wholesale accelerating to 10.9% in local currencies in the second half of FY2025/26 on the Phonak Infinio platform, which shows that a strong product cycle can still move share within a flat market. There is a coherent route to 6.5% at the manufacturer tier: wholesale prices hold while retail margins absorb the consumer price compression, so factory-gate revenue grows faster than consumer spend. Demant's own split is exactly that pattern under strain. But that argument supports the bottom of the published range, not the 10.1% and 11.7% figures circulating on secondary sites. Readers should forecast units — which EHIMA publishes and which is decelerating — and apply their own view of wholesale price, rather than accepting any published revenue CAGR for a market whose volume growth has halved twice in two years.

05

Market Dynamics

  • Demographic inevitability: the WHO figure Global Market Insights itself cites puts 1.5 billion people with some degree of hearing loss, against 23.16 million units sold a year
  • The FDA's over-the-counter category, effective 17 October 2022, which removed the professional gatekeeping requirement for adults with perceived mild-to-moderate loss and has put devices on retail shelves at $502 a pair
  • Retail vertical integration, which is where the margin now accrues: Demant's clinic revenue rose 8% in 2025 on acquisitions, and Sonova has renamed its dispensing arm Retail and reports it inside the same segment as Wholesale
  • Platform refresh cycles driving replacement rather than first fittings: GN's 5% organic growth in 2025 was attributed specifically to the ReSound Vivia platform, and Sonova's second-half Wholesale acceleration to 10.9% to Phonak Infinio
  • Rechargeability and connectivity as replacement triggers, which shorten the effective device life of an installed base that historically replaced every five to seven years
  • Reimbursement expansion in individual markets, which moves whole cohorts at once — and whose withdrawal does the same in reverse, as WS Audiology's citation of reduced United States benefit coverage shows
06

Market Segmentation

By Type

  • Behind-the-ear (BTE)
  • Receiver-in-the-ear / receiver-in-canal (RITE/RIC)
  • In-the-ear (ITE)
  • In-the-canal (ITC)
  • Completely-in-canal and invisible-in-canal (CIC/IIC)
  • Over-the-counter and self-fitting devices

By End User

  • Audiology clinics and hearing care retail networks
  • Independent hearing aid dispensers
  • Hospitals and ENT practices
  • Big-box and warehouse retail
  • Online and direct-to-consumer channels

By Application

  • Sensorineural hearing loss
  • Conductive and mixed hearing loss
  • Age-related hearing loss (presbycusis)
  • Noise-induced hearing loss
  • Paediatric hearing loss
07

Competitive Landscape

S

Sonova Holding AG

Stafa, Switzerland

The largest group in the industry by disclosed revenue and the one reshaping its portfolio most actively — divesting Consumer Hearing and renaming its two hearing businesses Wholesale and Retail. Its CHF 3,605.9 million of FY2025/26 continuing-operations revenue converts to roughly $4,587 million at our own approximate rate, which is more than half of the entire published 2025 market on its own. No share is disclosed and we assign none; trade commentary putting it between 25% and 31% carries no method and is not usable.

FY2025/26 (ended 31 March 2026, released 18 May 2026) group sales CHF 3,605.9 million, up 5.9% in local currencies and down 0.2% in Swiss francs, on continuing operations. The Hearing Instruments segment — Wholesale plus Retail — was reported at approximately CHF 3.35 billion, up 7.5% in local currencies, with Wholesale growth accelerating to 10.9% in local currencies in the second half on the Phonak Infinio and Sphere Infinio platforms. Normalised EBITA CHF 811.2 million, up 17.3% in local currencies; reported EBITA CHF 724.2 million. Consumer Hearing is being divested and is reported as discontinued operations, with FY2024/25 comparatives restated from the original CHF 3,865.4 million.

D

Demant A/S

Smorum, Denmark

The most important company in this analysis, because it is the only one that publishes its wholesale and retail revenue in the same statement — and the comparison settles what the published market measures. In 2025 its retail clinic revenue of DKK 10,724 million exceeded its external wholesale hearing-aid revenue of DKK 9,841 million. The manufacturer tier is less than half the money in a company that owns both ends. No share is disclosed.

2025 group revenue DKK 22,971 million against DKK 22,419 million, up 2% organic and 5% in local currencies. Hearing Aids external revenue — wholesale to third parties — DKK 9,841 million, down 2% reported from DKK 10,022 million; total Hearing Aids revenue including DKK 2,632 million of internal sales to its own retail, DKK 12,473 million. Hearing Care, the retail clinic business, DKK 10,724 million, up 8% reported on acquisitions. EBIT before special items DKK 3,960 million at a 17.2% margin. 2026 guidance of 3-6% organic growth. The company cited slower-than-normal hearing aid market growth and intense competition as drags on profitability.

W

WS Audiology A/S

Lynge, Denmark

The third large group, owner of the Signia and Widex brands, and the clearest evidence that the manufacturer tier is not growing: EUR 2,579 million of FY2024/25 revenue at 0% organic growth, against 10% the prior year, which it attributed partly to reduced benefit coverage in the United States. Privately held, so its figures reach the public only through trade-press reprints. No share is disclosed and we assign none.

FY2024/25 revenue EUR 2,579 million — roughly $2,796 million at our own approximate conversion — at 0% organic growth against 10% the prior year, attributed to broader economic slowdowns and reduced benefit coverage in the United States. Fourth-quarter revenue EUR 621 million at -1% organic, with EBITDA before special items of EUR 119 million at a 19.2% margin. Launches included Signia Insio Charge&Go CIC IX, Motion Charge&Go IX and Pure Charge&Go BCT IX, plus the Widex ALLURE platform and Widex Compass Cloud fitting software. FY2025/26 guidance of 0% to 4% organic growth, with first-half revenue of EUR 1.257 billion at flat organic growth.

G

GN Store Nord A/S (GN Hearing)

Ballerup, Denmark

The fourth large group, operating the ReSound and Beltone brands, and the only one of the four that grew organically in the mid single digits in 2025 — though at 5% after 10% and 13% in the two prior years, so it too is decelerating. It claims record-high market share across various markets on the ReSound Vivia platform but publishes no share figure, and we assign none.

Hearing division 2025 revenue DKK 7,214 million against DKK 7,104 million — roughly $1,048 million at our own approximate conversion — including a -1% impact from mergers and acquisitions and -2% from foreign exchange, with 5% organic growth after 10% in 2024 and 13% in 2023. Growth attributed to the ReSound Vivia platform, which the company says enabled record-high market share across various markets. 2026 Hearing division guidance of 3% to 7% organic revenue growth. A divisional profit figure circulating with these results does not reconcile against the revenue line, so no GN profit figure is used here.

S

Starkey Hearing Technologies

Eden Prairie, Minnesota, United States

The fifth major manufacturer and the only one of the five that discloses nothing at all, being privately held. Its absence is material: four disclosures already total about 1.34 times the published 2025 market, and Starkey is not in that sum. Named, characterised, and deliberately not sized.

Privately held hearing aid manufacturer with a United States manufacturing base, competing across the prescription channel alongside the four European groups. Publishes no revenue, unit or share figures, so it enters no arithmetic in this report.

A

Amplifon S.p.A.

Milan, Italy

A pure hearing care retailer of substantial scale that manufactures nothing, and therefore sits entirely outside every published definition of the hearing aids market. Its existence is part of the proof that the published figures are a manufacturer-tier measurement: a significant share of what consumers spend on hearing aids never appears in any of them. We found no revenue figure for Amplifon in this research pass and deliberately do not estimate one.

Operates a large international network of hearing care clinics, dispensing devices made by the four manufacturing groups and Starkey. Its revenue is retail dispensing and audiological services, the tier that Demant's own accounts show to be larger than wholesale and that no published hearing aid market size counts.

08

Recent Developments

26
2026European Hearing Instrument Manufacturers Association (EHIMA)

Reported that member companies collectively sold 23.16 million hearing aids globally in 2025, a 2.1% increase on 2024 — a sharp deceleration from 22.69 million in 2024 (+4.0%) and 21.81 million in 2023 (+7.7%), and far below every published revenue CAGR for the market.

26
2026Sonova Holding AG

Reported FY2025/26 results on 18 May 2026 with group sales of CHF 3,605.9 million, up 5.9% in local currencies and down 0.2% in Swiss francs, Wholesale growth accelerating to 10.9% in local currencies in the second half, and normalised EBITA up 17.3% to CHF 811.2 million — alongside a decision to divest Consumer Hearing, now reported as discontinued operations, and a renaming of Hearing Instruments to Wholesale and Audiological Care to Retail.

26
2026Demant A/S

Published its 2025 annual report showing group revenue of DKK 22,971 million with external wholesale hearing-aid revenue down 2% to DKK 9,841 million while Hearing Care retail revenue rose 8% to DKK 10,724 million — retail exceeding wholesale inside the same company — and cited slower-than-normal hearing aid market growth and intense competition as drags on profitability.

26
2026GN Store Nord A/S

Reported 2025 Hearing division revenue of DKK 7,214 million with 5% organic growth, following 10% in 2024 and 13% in 2023, attributed to the ReSound Vivia platform, and guided the division to 3% to 7% organic growth for 2026.

25
2025WS Audiology A/S

Reported FY2024/25 revenue of EUR 2,579 million at 0% organic growth, against 10% the prior year, attributing the flat result to broader economic slowdowns and reduced benefit coverage in the United States, and guided FY2025/26 to 0% to 4% organic growth.

22
2022U.S. Food and Drug Administration

Published the over-the-counter hearing aid final rule at 87 FR 50698 on 17 August 2022, effective 17 October 2022, creating an OTC category for air-conduction hearing aids for adults aged 18 and over with perceived mild-to-moderate hearing loss and repealing the prior conditions for sale, with devices already legally marketed required to comply by 14 April 2023 — the regulatory event behind a 42% fall in measured consumer prices since 2018.

09

Regulatory Landscape

The FDA over-the-counter hearing aid final rule, 87 FR 50698, published 17 August 2022 and effective 17 October 2022, established an OTC category at 21 CFR part 800 for air-conduction hearing aids that do not require surgical implantation, intended for people aged 18 and over with perceived mild-to-moderate hearing impairment. It amended 21 CFR parts 800, 801, 808 and 874, repealed the prior conditions for sale, revised labelling requirements and updated the Federal preemption exemption process. Devices already legally offered for sale before the effective date, including those with 510(k) clearance, had to comply by 14 April 2023, 240 days after publication. GAO noted the rule did not carry the 60-day delay the Congressional Review Act requires.Prescription hearing aids remain 510(k) devices under 21 CFR part 874 and are dispensed under state licensure regimes for audiologists and hearing aid dispensers. The OTC rule did not change that pathway; it created a parallel one, which is why the same manufacturers now sell into two channels with roughly a sevenfold price difference between them.Self-fitting air-conduction hearing aids were authorised through a separate De Novo classification before the OTC rule and are now the technical basis of most OTC products: the device must allow the user to program it to their own hearing without a professional fitting, which is the specific capability the OTC category requires.EU Medical Device Regulation 2017/745 governs hearing aids placed on the EU market, with notified-body conformity assessment and post-market surveillance. The EU has no equivalent of the United States OTC category, which is one reason European price and channel structures differ from American ones and why a global market figure blends two regulatory regimes.Reimbursement rather than regulation sets volumes in most countries. National systems in Denmark, Germany, France, the United Kingdom and Japan fund hearing aids through public or statutory schemes with their own tendering and price controls; in the United States traditional Medicare does not cover hearing aids, and coverage comes through Medicare Advantage supplemental benefits and employer plans. WS Audiology attributed a flat FY2024/25 directly to reduced benefit coverage in the United States, which shows how exposed unit volumes are to payer policy.EHIMA's unit statistics are the de facto register for this market, and they are a voluntary trade-association compilation of member sales rather than a regulatory filing. EHIMA does not publish what share of world units its members represent, so the 23.16 million figure for 2025 is a floor on global volume rather than a total.
10

Research Methodology

Secondary research

  • European Hearing Instrument Manufacturers Association (EHIMA), global hearing aid sales statistics — member companies sold 23.16 million units globally in 2025 (+2.1%), 22.69 million in 2024 (+4.0%) and 21.81 million in 2023 (+7.7%)
  • Global Market Insights, Hearing Aids Market, report GMI5082, published September 2025 — $8.3B (2024), $8.8B (2025), $15.5B (2034), 6.5% (2025-2034), with a published history from 2021, product, patient and channel segmentation and regional figures
  • Demant A/S, Annual Report 2025 and review of H2 2025 — group revenue DKK 22,971M; Hearing Aids external DKK 9,841M (-2%); Hearing Aids including internal sales DKK 12,473M; Hearing Care retail DKK 10,724M (+8%); EBIT before special items DKK 3,960M at 17.2%
  • Sonova Holding AG, FY2025/26 results, 18 May 2026 — group sales CHF 3,605.9M (+5.9% local currencies) on continuing operations; Hearing Instruments segment approximately CHF 3.35B; Wholesale +10.9% local currencies in H2; Consumer Hearing divested and reported as discontinued
  • Sonova Holding AG, Annual Report 2024/25 — group sales CHF 3,865.4M (+7.6% local currencies, +6.6% in CHF) before restatement for the Consumer Hearing divestment
  • WS Audiology A/S, FY2024/25 annual results — revenue EUR 2,579M at 0% organic growth; Q4 EUR 621M at -1% organic with EBITDA before special items of EUR 119M at 19.2%; FY2025/26 guidance 0-4% organic
  • GN Store Nord A/S, GN Annual Report 2025 — Hearing division revenue DKK 7,214M (2024: DKK 7,104M) with 5% organic growth after 10% in 2024 and 13% in 2023; 2026 guidance 3-7% organic
  • HearingTracker, What is the true cost of hearing aids in 2026 — survey of more than 1,100 buyers: $2,694 average per pair against $4,672 in 2018; $502 per pair over-the-counter against $3,432 prescription private pay; Costco $1,674 per pair
  • U.S. FDA, Medical Devices; Ear, Nose, and Throat Devices; Establishing Over-the-Counter Hearing Aids, final rule, 87 FR 50698, published 17 August 2022, effective 17 October 2022, compliance for legacy devices by 14 April 2023
  • Ken Research — $9.08B (2025) to $14.57B (2032) at 7.00%; MarketsandMarkets report 182461673 — $10.35B (2025) at 6.8% to 2030; Meticulous Research — $13.04B by 2032 at 5.7%; Fortune Business Insights via secondary sites — $15.11B (2025) to $29.58B (2032) at 10.1%, with a conflicting second version at $34.76B and 11.7%

Validation: The headline is one publisher's own base advanced at its own rate, labelled as interpolation: Global Market Insights' $8.8 billion for 2025 becomes $9.37 billion for 2026 and $13.67 billion for 2032 at 6.5%. The internal check is that the implied rate between our endpoints is 6.50%, identical to the stated rate. GMI was chosen because it carries a stated publication date and the longest published history in the set — five dated annual values from 2021 to 2025 — because it is the only source in the set read directly from the publisher's own page rather than through a search summary or secondary site, and because its $8.8 billion is the figure our reconciliation of disclosed manufacturer revenue lands on almost exactly. Five grounding tests were run. First, price per unit: EHIMA member companies sold 23.16 million hearing aids globally in 2025, so the published totals work out at $380 per aid on GMI's figure, $447 on MarketsandMarkets' and $652 on the Fortune figure circulating on secondary sites. HearingTracker's survey of more than 1,100 buyers puts the measured average transaction at $2,694 per pair, or $1,347 per aid, so 23.16 million units at consumer prices is roughly $31.2 billion — about 3.5 times GMI's total. The published figures are therefore manufacturer-tier revenue, and no publisher in the set says so. Second, Demant proves the two tiers from inside one company: in 2025 its Hearing Care retail revenue of DKK 10,724 million exceeded its external wholesale hearing-aid revenue of DKK 9,841 million, and its own retail arm bought DKK 2,632 million of aids internally while selling DKK 10,724 million of hearing care. Third, summing disclosed revenue: Sonova CHF 3,605.9 million, Demant DKK 22,971 million, WS Audiology EUR 2,579 million and GN's Hearing division DKK 7,214 million total about $11,769 million at our own approximate conversions, which is 1.34 times GMI's $8.8 billion, 1.30 times Ken Research's $9.08 billion and 1.14 times MarketsandMarkets' $10.35 billion — with Starkey, privately held, not in the sum and Amplifon, a pure retailer, outside every published definition. Fourth, the reconciliation: stripping retail out where it is disclosed gives Demant's wholesale at about $1,430 million, GN at $1,048 million and WS Audiology at about $2,796 million, totalling $5,274 million, to which Sonova's Wholesale and Starkey must be added; at plausible magnitudes for those two the manufacturer tier totals roughly $8.1 to $8.8 billion, which is GMI's figure. So the published figures are approximately right for the tier they measure and roughly 3.5 times too small for the tier a reader assumes. Fifth, a coherence test on growth: EHIMA unit growth decelerated from 7.7% to 4.0% to 2.1% across 2023-2025, measured consumer prices fell 42% from 2018 to 2026, and the manufacturers' own 2025 growth was roughly 2 to 3% — Demant's external wholesale down 2%, WS Audiology 0% organic, GN 5% organic — against published CAGRs of 5.6% to 11.7%. These are scope and plausibility tests, not market estimates. All currency conversions are ours at approximate rates implied by the USD figures the sources' own coverage printed alongside the local-currency ones; HearingTracker's prices are dated 2026 against our 2025 price base and are a survey of self-selected buyers rather than an average selling price; EHIMA's series covers member companies only and is therefore a floor on world units, with no published figure for members' share of global volume; the Sonova Wholesale and Starkey magnitudes used in the fourth test are our own and are published nowhere, and they appear in the notes file only; and dividing company revenue into a published market total compares differently constructed numbers. Regional, country and channel splits are published as empty arrays or plain strings: the only source offering them presents no method, and its own e-commerce figure of $3.2 billion for 2024 — 38.6% of its total — is not credible in an industry where Demant's clinic revenue alone is DKK 10,724 million. No vendor market share is published because none is disclosed, and the trade commentary putting Sonova between 25% and 31% carries no method.

11

Strategic Takeaways

Decide which tier you mean. The published $8.8 billion is manufacturer revenue at about $380 per aid. Consumer spend on the same 23.16 million units is roughly $31 billion at measured transaction prices. The gap is the dispensing channel and no publisher labels it.

Use the unit series, not the revenue series. EHIMA publishes global member unit sales, and they grew 7.7%, then 4.0%, then 2.1% across 2023-2025 — a deceleration no published revenue CAGR reflects.

Read Demant's two revenue lines together. Retail at DKK 10,724 million rising 8% against wholesale at DKK 9,841 million falling 2%, in the same company, in the same year, is the clearest single piece of evidence about where the money in this industry has moved.

Note that four manufacturers already disclose more revenue than three of the five published markets contain — and that Starkey is private and Amplifon manufactures nothing, so neither appears in any of them.

Treat the FDA over-the-counter rule as a price event, not a volume event. OTC pairs transact at $502 against $3,432 prescription, measured prices are down 42% since 2018, and units grew 2.1% last year. That combination does not produce a double-digit revenue CAGR.

12

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.